Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA (Vascular InterVentional Advances) Annual Conference have been announced. Leading physicians and researchers will present results from 21 clinical trials, from Monday, October 31, to Wednesday, November 2, at Wynn Las Vegas.
An interim safety analysis from ECZTEND, an open-label, 5-year extension trial, demonstrated consistent safety from the parent trials for up to 3.5 years of Adbry (tralokinumab-ldrm) treatment in
Pivotal results for efficacy and safety of Cosentyx (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology
/PRNewswire/ -- Leading physicians and researchers will present results from 21 clinical trials from Monday, October 31, to Wednesday, November 2, at the...
Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe...